A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
- Conditions
- Huntington Disease
- Interventions
- Drug: ACR16Other: Placebo
- First Posted Date
- 2008-07-29
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT00724048
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇨🇦University of Alberta Glenrose Rehab Hospital, Edmonton, Alberta, Canada
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 559
- Registration Number
- NCT00696332
- Locations
- 🇧🇪
Academic Hospital University of Leuven - ALS dept, Leuven, Belgium
🇫🇷C.H.U. de Montpellier - Hopital Gui de Chauliac - Service des Explorations Neurologiques, Montpellier Cedex 5, France
🇨🇦Montreal Neurological Institute, Montreal, Quebec, Canada
Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome
- Conditions
- Multiple Sclerosis
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 481
- Registration Number
- NCT00666224
A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
- Conditions
- Huntington's Disease
- Interventions
- Drug: ACR16Drug: Placebo
- First Posted Date
- 2008-04-23
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 437
- Registration Number
- NCT00665223
- Locations
- 🇪🇸
Hospital Universitario La Fe, Avda. Campanar 21,, Valencia, Spain
🇩🇪Westfaelische Wilhelms-Universitaet Muenster, Klinik fur Neurologie, Muenster, North Rhine-Westphalia, Germany
🇦🇹LKH -Univ. Klinikum Graz, Universitaetsklinik fur Psychiatrie Graz, Graz, Styria, Austria
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1331
- Registration Number
- NCT00605215
- Locations
- 🇺🇸
Teva Investigational Site 1263, Shreveport, Louisiana, United States
🇷🇴Teva Investigational Site 5219, Sibiu, Romania
🇩🇪Teva Investigational Site 6402, Berlin, Germany
Albuterol HFA MDI in Pediatric Participants With Asthma
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT00577655
- Locations
- 🇺🇸
Asthma & Allergy Associates, PC, Elmira, New York, United States
🇺🇸Virginia Adult & Pediatric Allergy & Asthma, Richmond, Virginia, United States
🇺🇸Pediatric Care Medical Group, Inc., Huntington Beach, California, United States
A Study to Evaluate Hormone Patterns and Ovarian Follicular Activity With DR-1021
- Conditions
- Healthy
- Interventions
- Drug: DR-1021Drug: Mircette®Drug: Kariva®
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2021-11-18
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 61
- Registration Number
- NCT00544882
- Locations
- 🇺🇸
Duramed Investigational Site, Seattle, Washington, United States
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Albuterol-HFA-BAIDrug: Albuterol-HFA-MDI
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2022-09-07
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT00530062
- Locations
- 🇺🇸
Teva Clinical Study Site, Lakewood, Colorado, United States
🇺🇸Clinical Study Site, Lake Oswego, Oregon, United States
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
- First Posted Date
- 2007-07-31
- Last Posted Date
- 2021-11-02
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 1106
- Registration Number
- NCT00509145
- Locations
- 🇵🇱
Teva Investigational Site 5320, Gorzow Wielkopolski, Poland
🇷🇺Teva Investigational Site 5026, Saint-Petersburg, Russian Federation
🇷🇺Teva Investigational Site 5023, St. Petersburg, Russian Federation
Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2021-12-28
- Lead Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00462943
- Locations
- 🇨🇦
Teva Investigational Site 313, Montreal, Canada
🇫🇷Teva Investigational Site 327, Strasbourg, France
🇺🇸Teva Investigational Site 303, Los Angeles, California, United States